{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-24-000055","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.781317+00:00","generated_at":"2026-05-31T21:47:30.533755+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Salarius Pharmaceuticals announces FDA partial clinical hold on seclidemstat trial after grade 4 adverse event","bullets":["A patient in MDACC's trial of seclidemstat + azacitidine for MDS/CMML experienced a serious unexpected grade 4 adverse event.","FDA placed partial clinical hold; no new patients may enroll, but current subjects benefiting may continue treatment.","Salarius will support MDACC in analyzing data and responding to FDA questions."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-24-000055","json":"https://secwatch.observer/filing/0001615219-24-000055.json","markdown":"https://secwatch.observer/filing/0001615219-24-000055.md","text":"https://secwatch.observer/filing/0001615219-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000055/0001615219-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000055/flks-20240709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:47:30.533755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}